Please use this identifier to cite or link to this item:
Title: Positron emission tomographic imaging in drug discovery
Authors: Ghosh, Krishna Kanta
Padmanabhan, Parasuraman
Yang, Chang-Tong
Palanivel, Mathangi
Mishra, Sachin
Halldin, Christer
Gulyás, Balázs
Keywords: Science::Medicine
Issue Date: 2022
Source: Ghosh, K. K., Padmanabhan, P., Yang, C., Palanivel, M., Mishra, S., Halldin, C. & Gulyás, B. (2022). Positron emission tomographic imaging in drug discovery. Drug Discovery Today, 27(1), 280-291.
Journal: Drug Discovery Today
Abstract: Positron emission tomography (PET) is an extensively used nuclear functional imaging technique, especially for central nervous system (CNS) and oncological disorders. Currently, drug development is a lengthy and costly pursuit. Imaging with PET radiotracers could be an effective way to hasten drug discovery and advancement, because it facilitates the monitoring of key facets, such as receptor occupancy quantification, drug biodistribution, pharmacokinetic (PK) analyses, validation of target engagement, treatment monitoring, and measurement of neurotransmitter concentrations. These parameters demand careful analyses for the robust appraisal of newly formulated drugs during preclinical and clinical trials. In this review, we discuss the usage of PET imaging in radiopharmaceutical development; drug development approaches with PET imaging; and PET developments in oncological and cardiac drug discovery.
ISSN: 1359-6446
DOI: 10.1016/j.drudis.2021.07.025
Rights: © 2021 Elsevier Ltd. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:LKCMedicine Journal Articles

Citations 50

Updated on Nov 26, 2022

Web of ScienceTM
Citations 50

Updated on Nov 28, 2022

Page view(s)

Updated on Nov 30, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.